The new problem in Philippine weight management is not scarcity. It is choice. Four years ago, a woman who wanted medical help losing weight in Manila had a narrow menu and a physician willing to prescribe around it. Then Mounjaro arrived in January 2026, the first dual-action medication of its class, approved here for both obesity and type 2 diabetes, a breadth its American sibling Zepbound does not carry. Wegovy followed in April, the dedicated weight-loss formulation of se

Saxenda, an FDA-approved weight loss medication, functions as a glucagon-like peptide-1 (GLP-1) receptor agonist to help reduce appetite...